Company Overview: Immunovaccine

Industry News

15 Jul

Immunovaccine’s DPX-Survivac Receives Orphan Drug Designation from the FDA for the Treatment of Ovarian Cancer.

Immunovaccine Inc. (“Immunovaccine” or the “Company”) (IMV.TO)(IMMVF), a clinical stage vaccine and immunotherapy company, today announced that the U.S. Food and Drug Administration (“FDA”), has granted orphan drug status to DPX-Survivac for the treatment of ovarian cancer. This designation is valid for all applications of DPX-Survivac in ovarian cancer...

Read more

8 Jul

Immunovaccine and PharmAthene Sign Exclusive Worldwide License Agreement to Develop and Commercialize an Anthrax Vaccine Formulated in DepoVax(TM)

Immunovaccine Inc. (IMV.TO)(IMMVF), a clinical stage vaccine and immunotherapy company, announced today that it has entered into an exclusive worldwide license agreement with PharmAthene, Inc. (NYSE MKT:PIP) to develop and commercialize a Recombinant Protective Antigen Anthrax vaccine (rPA) candidate utilizing Immunovaccine’s proprietary DepoVax™ vaccine platform. Under the terms of...

Read more

2 Jul

Immunovaccine Publishes Clinical Results With DPX-Survivac in Combination With an Immune-Modulating Compound

Safety and immunogenicity data from Phase 1 trial with company’s lead cancer immunotherapy candidate published in Oncoimmunology Immunovaccine Inc. (“Immunovaccine” or the “Company”) (IMV.TO)(IMMVF), a clinical stage vaccine and immunotherapy company, today announced that data from its completed Phase 1 clinical trial with lead cancer immunotherapy candidate, DPX-Survivac, was...

Read more

25 Jun

Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer

Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it has entered into a non-exclusive clinical trial collaboration with Incyte Corporation (Nasdaq: INCY) to evaluate the combination of Immunovaccine’s novel T cell activating immunotherapy, DPX-Survivac, with Incyte’s investigational oral indoleamine...

Read more

21 May

Immunovaccine to Present at Upcoming Investor Conferences

Immunovaccine Inc. (“Immunovaccine” or the “Company”) (IMV.TO)(IMMVF), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at two upcoming U.S. investor-focused conferences, the 2015 Marcum MicroCap Conference, held May 27-28, 2015 in New York, NY and the LD Micro Invitational 2015, held June 1-3,...

Read more

27 Apr

Immunovaccine Joins the OTCQX Marketplace in the United States

Immunovaccine Inc. (“Immunovaccine” or the “Company“) (IMV.TO)(IMMVF), a clinical stage vaccine and immunotherapy company, has been approved to trade on the OTCQX® Best Marketplace in the United States under the symbol “IMMVF”. The Company will continue to trade on the Toronto Stock Exchange under the symbol “IMV”. The OTCQX...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address